| Metastatic castration-resistant prostate cancer
Zytiga vs Yonsa
Side-by-side clinical, coverage, and cost comparison for metastatic castration-resistant prostate cancer.Deep comparison between: Zytiga vs Yonsa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYonsa has a higher rate of injection site reactions vs Zytiga based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yonsa but not Zytiga, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zytiga
Yonsa
At A Glance
Oral
Daily
CYP17 inhibitor
Oral
Daily
CYP17 inhibitor
Indications
- Metastatic castration-resistant prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
- Metastatic castration-resistant prostate cancer
Dosing
Metastatic castration-resistant prostate cancer 1,000 mg orally once daily with prednisone 5 mg orally twice daily; take on an empty stomach (no food 2 hours before or 1 hour after).
Metastatic Castration-Sensitive Prostate Carcinoma 1,000 mg orally once daily with prednisone 5 mg orally once daily; take on an empty stomach (no food 2 hours before or 1 hour after).
Metastatic castration-resistant prostate cancer 500 mg (four 125 mg tablets) orally once daily with or without food in combination with methylprednisolone 4 mg twice daily; concurrent GnRH analog or bilateral orchiectomy required.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory infection, cough, headache
Serious Cardiac failure, hepatotoxicity, hypokalemia (Grade 3-4), arrhythmia, cardiorespiratory arrest
Postmarketing Non-infectious pneumonitis, myopathy including rhabdomyolysis, fulminant hepatitis including acute hepatic failure and death, QT prolongation and Torsades de Pointes, anaphylactic reactions
Most common (>10%) Fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection, contusion.
Serious Cardiac failure, arrhythmia, hepatotoxicity, hypokalemia, fluid retention.
Postmarketing Non-infectious pneumonitis, myopathy including rhabdomyolysis, fulminant hepatitis including acute hepatic failure, QT prolongation and Torsades de Pointes, anaphylactic reactions.
Pharmacology
Abiraterone acetate is converted in vivo to abiraterone, a selective inhibitor of CYP17 (17alpha-hydroxylase/C17,20-lyase) that blocks androgen biosynthesis in testicular, adrenal, and prostatic tumor tissues, thereby reducing serum testosterone and other androgens in patients with prostate cancer.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits CYP17 (17alpha-hydroxylase/C17,20-lyase), blocking androgen production in testicular, adrenal, and prostatic tumor tissues to suppress androgen-sensitive prostate cancer growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zytiga
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (9/12)
Yonsa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Zytiga
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Yonsa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zytiga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Yonsa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Janssen CarePath Savings Program: ZytigaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.